Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study pharmacokinetic and biodistribution and FCU1 function of TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas

Next Previous
X
Search
Trial Profile

To study pharmacokinetic and biodistribution and FCU1 function of TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Pharmacokinetics

    • Most Recent Events

    • 15 Mar 2023 According to a Transgene media release, company will be presenting eight posters on its clinical and preclinical immunotherapies at the AACR (American Association for Cancer Research) Annual Meeting 2023, which will take place in Orlando, Florida, USA, Tues Apr 18, 2023; 9:00 a.m. - 12:30 p.m. ET
    • 16 Mar 2022 According to a Transgene media release, this trial is expected to be completed by mid-2022. Comprehensive translational data will be presented in the fourth quarter of 2022.
    • 01 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top